After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%

Unity Biotechnology Inc., whose clinical trial in osteoarthritis of the knee failed last month in clearing away dead cells thought to play a role in inflammation, will cut 30% of its workforce to focus its remaining cash on eye and brain diseases. One of the first wave of so-called aging drug companies — concentrating on therapies to tackle aging-associated diseases — the South San Francisco company (NASDAQ: UBX) said Tuesday it plans to end the year with about 75 full-time employees. The…

Click to view original post